About Enhancer
| Enhancer ID: | E_00410 |
| Species: | Homo sapiens |
| Position : | chr14:23912000-23912961   |
| Year: | 2021 |
| Title: | Genetic Variation in Enhancers Modifies Cardiomyopathy Gene Expression and Progression. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 33478249 |
| Tissue Ontology ID: | UBERON:0002084 |
| Cell Source: | human iPSC-derived cardiomyocytes |
| Cell Ontology ID: | CL:0000746 |
| Experiment Type: | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay; Engineered heart tissue functional assay |
| High Throughput Method: | Promoter Capture Hi-C; H3K27ac ChIP-seq; ATAC-seq; H3K4me3 ChIP-seq; CTCF ChIP-seq; cardiac TF ChIP-seq |
| Low Throughput Method: | qRT-PCR |
About Target Gene
| Target gene : | MYH7 |
About TF
| TF name : | NKX2-5 |
About Regulatory State
| Regulatory State : | Active |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| NKX2-5 | Physiological factors | reactome | 12 |
| NKX2-5 | Regulation of nuclear SMAD2/3 signaling | pid | 82 |
| NKX2-5 | YAP1- and WWTR1 (TAZ)-stimulated gene expression | reactome | 29 |
| NKX2-5 | Hs_Heart_Development_WP1591_90186 | wikipathways | 28 |
Enhancer Associated Network
Overlapping Enhancers (hg19)
7 found
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_00032 | chr14:23912000-23912961 | left cardiac ventricle | ventricular cardiomyocyte | cardiomyopathy |
| E_00033 | chr14:23912000-23912961 | left cardiac ventricle | ventricular cardiomyocyte | cardiomyopathy |
| E_00155 | chr14:23912000-23912961 | heart left ventricle | cardiac muscle cell | NA |
| E_00156 | chr14:23912000-23912961 | heart left ventricle | cardiac muscle cell | NA |
| E_00157 | chr14:23912000-23912961 | heart left ventricle | cardiac muscle cell | NA |
| E_00158 | chr14:23912000-23912961 | heart left ventricle | cardiac muscle cell | NA |
| E_00411 | chr14:23912000-23912961 | NA | NA | NA |
Expression of Target Genes for the Enhancer